Freshfields, Latham advise on AstraZeneca's acquisition of Icosavax

Karry Lai

December 12, 2023

X
LinkedIn
Email
Show more sharing options

Close-up medical syringe with a vaccine.

The Anglo-Swedish pharmaceutical company will acquire the US-based clinical stage biopharmaceutical business in a $1.1 billion deal

Unlock this content.

The content you are trying to view is exclusive to our subscribers.

To unlock this content:

Take a Free Trial or Login

Topics

Karry Lai

Managing editor

Karry is managing editor of IFLR. She manages the team and is responsible for IFLR's content. She also sits on the editorial judging panels of IFLR's global awards and the Women in Business Law Awards. Before joining the legal media industry, she was project manager at a startup focused on sustainable lifestyle media and events.